In the first issue of the Implen NanoPhotometer® Journal Club: Nanomedicine Edition, the work of Wang et. al. recently published in the Chemical Engineering Journal providing an effective new approach for the treatment of malignant bone tumors is being highlighted. Malignant bone tumors are frequent and difficult to cure, which is still a major clinical challenge as the bone microenvironment provides a “barrier” for bone tumors to resist clinical chemoradiotherapy, implying that molecules targeting tumor cells alone cannot effectively target bone tumor cells.
In this study, a novel bone tumor cell-targeting nanosystem for chemo-photothermal synergistic treatment of malignant bone tumors was designed. A bone tumor cell-targeting peptide (BTTP) was covalently attached to the surface of the nanosystem. The nanosystem was constructed by hybridization of a core Mn-Co metal-organic framework and polydopamine as the shell (TM@P). The TM@P/DOX nanosystem could be first targeted to the bone damage interface by the bone-targeting peptide. With Doxorubicin (DOX) loaded onto the TM@P surface (TM@P/DOX), the nanosystem targeted bone tumor cells and effectively inhibited bone tumor growth and osteolysis and also enhanced the contrast of bone tumor (MRI). Collectively, this study suggests that targeted drug delivery for bone tumors is feasible, providing a new and effective strategy for targeted therapy of bone tumors.
For characterization of the nanosystem, of The ultraviolet–visible (UV–Vis) spectra of samples were determined by the Implen NanoPhotometer®.
|